How do biotech companies move QA from late-stage gatekeeper into an early, risk-appropriate technical partner? Andrea Bell, VP and Global Head of Quality Assurance for BioNTainer at BioNTech, breaks down what phase-appropriate quality looks like across the lifecycle and why the barriers to getting there are cultural rather than procedural.
Andrea and Nick get into the real cost of late QA involvement, how risk-based rigor differs from uniform rigor, what makes a quality management review actually function, and how QA earns credibility with technical teams.
A few of Andrea's key takeaways:
Late QA involvement costs money and removes the option to remediate cheaply
Most of the cost of poor quality sits below the waterline in scrap, cycle time, investigations, and reputation
Early means early in the decision forums, not just early in the lifecycle
Risk-based rigor isn't looser rigor. Uniform checklists are a weaker position and agencies will challenge them
The barriers to embedding QA earlier are quality culture and reporting structure, not procedure
Data only makes QA proactive if people are empowered to act on it
QA earns credibility by co-authoring the argument you'll make to the regulator, not by signing off at the end
About Andrea Bell
Andrea Bell is Vice President, Global Head of Quality Assurance for BioNTainer at BioNTech SE, with more than 25 years in biotechnology building quality and CMC organizations across RNA, biologics, and small molecule programs. She previously held leadership roles at Vir Biotechnology, Alnylam Pharmaceuticals, and Biogen. She holds a doctorate in global public health, a master's in quality assurance and regulatory affairs, an MBA in international business, and a bachelor's in biology.
About The FDA Group
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/
